Tech Company Financing Transactions
TRexBio Funding Round
TRexBio closed a $50 million venture capital round on 1/27/2026. Investors included Affinity Asset Advisors, Alexandria Venture Investments and Avego Healthcare Capital.
Transaction Overview
Company Name
Announced On
1/27/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells ("Tregs") in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
681 Gateway Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Johnston Erwin
Chief Medical Officer
Ovid Trifan
Chief Scientific Officer
Melanie Kleinschek
VP - Bus. Development
Laura Berner
Browse more venture capital transactions:
Prev: 1/27/2026: Fortitude Biomedicines venture capital transaction
Next: 1/27/2026: Phia venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs